Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
OwnerMaria Dorly Del Curto, Daniela Chicco +1inventors
InventorsMaria Dorly Del Curto, Daniela Chicco, Pierandrea Esposito
Life of this patent
Estimating the term…
Abstract
Lipid nanoparticles loaded with drugs, such as peptides or proteins, are herein described. A process for obtaining them as well as their use for the preparation of a pharmaceutical composition is also disclosed. According to a preferred embodiment, the drug is a LHRH analogue, more preferably a LHRH antagonist, and the lipid matrix comprises at least 70% w/w of monoglycerides.
Claims23
Lipid nanoparticles comprising a drug, a lipid matrix and a surfactant characterized in that said drug is a peptide or a protein and said lipid matrix has a monoglyceride content which is at least 70% w/w, the percentage being based on the weight of the lipid matrix.
Lipid nanoparticles according to any of preceding claims characterized in that said surfactant is selected among synthetic phospholipids, their hydrogenated derivatives and mixtures thereof, sphingolipids and glycosphingolipids, saturated or unsaturated fatty acids, fatty alcohols, polyoxyethylene-polyoxypropylene copolymers, ethoxylated fatty acids as well as esters or ethers thereof, or a combination of two or more of the above mentioned.
Lipid nanoparticles according to any of the preceding claims characterized in that said nanoparticles also comprise other pharmaceutically acceptable excipients.
Lipid nanoparticles according to any of the preceding claims characterized in that said nanoparticles are in a range from 1 nm to 3 μm.
Lipid nanoparticles according to any of the preceding claims for use as a medicament.
A pharmaceutical composition containing lipid nanoparticles according to any of the preceding claims and a pharmaceutically acceptable carrier, diluent or excipient thereof.
Process for the production of lipid nanoparticles according to any of preceding claims comprising or consisting of the steps of:
- incorporation of the drug into the lipid phase and dissolution of the surfactant and optionally the co-surfactant in the aqueous phase, under controlled heating conditions and addition to the aqueous phase
- mixing of the lipid phase with the aqueous phase
- applying a High Pressure Homogenization to the obtained pre-emulsion and
- cooling down the nano-emulsion under controlled temperature conditions.
Dependencies are inferred from the claim text.